Summary
We investigated apoptosis induction by sulforaphane on three cell lines characterized by a different p53 status. In particular, we used p53-knock-out fibroblasts from newborn mice transfected with the p53-Ser220 mutation, observed in Li-Fraumeni Syndrome patients, as a model of mutated p53 status. Moreover, immortalized fibroblasts from newborn mice expressing or lacking p53 (p53 +/+ andp53-/-, respectively) have been used to verify whether mutated p53 status could prevent sulforaphane-induced apoptotic events. Sulforaphane was able to induce apoptosis on all three cell lines. Indeed, the caspase-3 assays and poly(ADP-ribose)polymerase (PARP) cleavage data indicated that sulforaphane stimulated caspase-3-like activity and degradation of PARP. However, cells with a wild-type or mutated p53 appeared to be more sensitive to the effects of sulforaphane than cells lacking p53. Taken together, our results suggest that sulforaphane could act by a p53-independent pathway. For this reason, sulforaphane can be viewed as a novel agent useful not only in the treatment of Li-Fraumeni-associated tumors but also drug resistant tumors where p53 dysregulation is a feature.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fisher DE: The p53 tumor suppressor: Critical regulator of life and death in cancer. Apoptosis 6: 7–15, 2001
Sigal A, Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60: 6788–6793, 2000
Iwamoto KS, Mizuno T, Ito T, Tsuyama N, Kyoizumi S, Seyama T: Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res 56: 3862–3865, 1996
Shaulsky G, Goldfinger N, Rotter V: Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res 51: 5232–5237, 1991
Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 145: 702–714, 1994
Crook T, Vousden KH: Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 11: 3935–3940, 1992
Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nat Genetic 4: 42–45, 1993
Wang X-J, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR, Roop DR: Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H172H mutant and p53-knockout mice after chemical carcinogenesis: Evidence for gain of function. Mol Carcinog 23: 185–192, 1998
Blandino G, Levine AJ, Oren M: Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477–485, 1999
Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germ line p53 mutations in a familiar syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233–1238, 1990
Li FP, Fraumeni JF: Soft-tissue sarcomas, breast cancer and other neoplasms: a familial syndrome? Ann Intern Med 71: 747–752, 1969
Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54: 1298–1304, 1994
Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358–5362, 1988
Varley J: Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21: 313–320, 2003
Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P: Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 91: 3147–3150, 1994
Gao X, Dinkova-Kostova AT, Talalay P: Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc Natl Acad Sci USA 98, 15221–15226, 2001
Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A: Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA 99: 7610–7615, 2002
Chung FL, Conaway CC, Rao CV, Reddy B: Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 21: 2287–2291, 2000
Ye L, Zhang Y: Total intracellular accumulation levels of dietary isothiocyanates determine their activity in elevation of cellular glutathione and induction of Phase 2 detoxification enzymes. Carcinogenesis 22: 1987–1992, 2001
Brooks JD, Paton VG, Vidanes G: Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev 10: 949–954, 2001
Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S: Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62: 5196–5203, 2002
Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S, Gasc N, Tulliez J, Terce F: Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60: 1426–1433, 2000
Bonnesen C, Eggleston IM, Hayes JD: Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res 61: 6120–6130, 2001
Chiao JW, Chung FL, Kancherla R, Ahmed T, Mittelman A, Conaway CC: Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. Int J Oncol 20: 631–636, 2002
Singh AV, Xiao D, Lew KL, Dhir R, Singh SV: Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 25: 83–90, 2004
Fimognari C, Nüsse M, Cesari R, Iori R, Cantelli-Forti G, Hrelia P: Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis 23: 581–586, 2002
Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346–355, 1994
Cerone MA, Marchetti A, Bossi G, Blandino G, Sacchi A, Soddu S: P53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts. Cell Death Differ 7: 506–508, 2000
Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1–16, 1997
Cheng J, Haas M: Frequent mutations in p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10: 5502–5509, 1990
Myzak MC, Karplus PA, Chung F-L, Dashwood RH: A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64: 5767–5774, 2004
Fu M, Wang C, Zhang X, Pestell RG: Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol 68: 1199–1208, 2004
Harvey DM, Levine AJ: p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev 5: 2375–2385, 1991
Rittling SR, Denhardt DT: p53 mutations in spontaneously immortalized 3T12 but not 3T3 mouse embryo cells. Oncogene 7: 935–942, 1992
Zhang Y: Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis 21: 1175–1182, 2000
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fimognari, C., Sangiorgi, L., Capponcelli, S. et al. A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug. Invest New Drugs 23, 195–203 (2005). https://doi.org/10.1007/s10637-005-6727-y
Issue Date:
DOI: https://doi.org/10.1007/s10637-005-6727-y